Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 6, Issue 1 , Pages 70-74 , January 2010

Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: Clinical observations as a basis for power calculations and safety analysis

References 

  1. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology. 1997;49:1284–1288
  2. Magherini A, Litvan I. Cognitive and behavioral aspects of PSP since Steele, Richardson and Olszewski's description of PSP 40 years ago and Albert's delineation of the subcortical dementia 30 years ago. Neurocase. 2005;11:250–262
  3. Menza MA, Cocchiola J, Golbe LI. Psychiatric symptoms in progressive supranuclear palsy. Psychosomatics. 1995;36:550–554
  4. Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP International Workshop. Neurology. 1996;47:1–9
  5. Cordato NJ, Pantelis C, Halliday GM, Velakoulis D, Wood SJ, Stuart GW, et al. Frontal atrophy correlates with behavioral changes in progressive supranuclear palsy. Brain. 2002;125:789–800
  6. Albert ML, Feldman RG, Willis AL. The “subcortical dementia” of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 1974;37:121–130
  7. Kish SJ, Chang LJ, Mirchandani L, Shannak K, Hornykiewicz O. Progressive supranuclear palsy: relationship between extrapyramidal disturbances, dementia, and brain neurotransmitter markers. Ann Neurol. 1985;18:530–536
  8. Ruberg M, Javoy-Agid F, Hirsch E, Scatton B, L'Heureux R, Hauw JJ, et al. Dopaminergic and cholinergic lesions in progressive supranuclear palsy. Ann Neurol. 1985;18:523–529
  9. Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti BJ, Constantine GM, et al. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. J Neurol. 2006;253:242–247
  10. Litvan I. Cholinergic approaches to the treatment of progressive supranuclear palsy. J Neural Transm. 1994;42(Suppl):275–281
  11. Atack JR, Litvan I, Thal LJ, May C, Rapoport SI, Chase TN. Cerebrospinal fluid acetylcholinesterase in progressive supranuclear palsy: reduced activity relative to normal subjects and lack of inhibition by oral physostigmine. J Neurol Neurosurg Psychiatry. 1991;54:832–835
  12. Whitehouse PJ, Martino AM, Marcus KA, Zweig RM, Singer HS, Price DL, et al. Reductions in acetylcholine and nicotine binding in several degenerative diseases. Arch Neurol. 1988;45:722–724
  13. Nardone R, Florio I, Lochner P, Tezzon F. Cholinergic cortical circuits in Parkinson's disease and in progressive supranuclear palsy: a transcranial magnetic stimulation study. Exp Brain Res. 2005;163:128–131
  14. Tagliavini F, Pilleri G, Gemignani F, Lechi A. Neuronal loss in the basal nucleus of Meynert in progressive supranuclear palsy. Acta Neuropathol (Berl). 1983;61:157–160
  15. Kasashima S, Oda Y. Cholinergic neuronal loss in the basal forebrain and mesopontine tegmentum of progressive supranuclear palsy and corticobasal degeneration. Acta Neuropathol (Berl). 2003;105:117–124
  16. Juncos JL, Hirsch EC, Malessa S, Duyckaerts C, Hersh LB, Agid Y. Mesencephalic cholinergic nuclei in progressive supranuclear palsy. Neurology. 1991;41:25–30
  17. Litvan I, Gomez C, Atack JR, Gillespie M, Kask AM, Mouradian MM, et al. Physostigmine treatment of progressive supranuclear palsy. Ann Neurol. 1989;26:404–407
  18. Blin J, Mazetti P, Mazoyer B, Rivaud S, Ben Ayed S, Malapani C, et al. Does the enhancement of cholinergic neurotransmission influence brain glucose kinetics and clinical symptomatology in progressive supranuclear palsy?. Brain. 1995;118:1485–1495
  19. Kertzman C, Robinson DL, Litvan I. Effects of physostigmine on spatial attention in patients with progressive supranuclear palsy. Arch Neurol. 1990;47:1346–1350
  20. Litvan I, Phipps M, Pharr VL, Hallett M, Grafman J, Salazar A. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology. 2001;57:467–473
  21. Fabbrini G, Barbanti P, Bonifati V, Colosimo C, Gasparini M, Vanacore N, et al. Donepezil in the treatment of progressive supranuclear palsy. Acta Neurol Scand. 2001;103:123–125
  22. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–198
  23. Tucha O, Lange KW. The Tower of London—German Version. Göttingen: Hogrefe. 2004;
  24. Memory Clinic-NPZ . The Consortium to Establish a Registry of Alzheimer's Disease CERAD-Plus. Basel: Memory Clinic-NPZ; 2005;
  25. Haerting C, Markowitsch HJ, Neufeld H, Calabrese P, Deisinger K, Kessler J. Wechsler Gedächtnistest-revidierte Fassung. Deutsche Adaptation der revidierten Fassung der Wechlser Memory Scale. Bern: Huber; 2000;
  26. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308–2314
  27. Brody AL, Saxena S, Silverman DH, Alborzian S, Fairbanks LA, Phelps ME, et al. Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine. Psychiatry Res. 1999;91:127–139
  28. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med. 2004;351:2509–2518

PII: S1552-5260(09)00106-X

doi: 10.1016/j.jalz.2009.04.1231

Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 6, Issue 1 , Pages 70-74 , January 2010

Article Tools

* Image Usage & Resolution